Section Arrow
IRON.NASDAQ
- Disc Medicine
Quotes are at least 15-min delayed:2026/11/04 14:31 EST
Regular Hours
Last
 83.005
+1.845 (+2.27%)
Day High 
83.26 
Prev. Close
81.16 
1-M High
85 
Volume 
228.21K 
Bid
82.92
Ask
83.12
Day Low
80.78 
Open
81.5 
1-M Low
55 
Market Cap 
3.60B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 78.98 
20-SMA 70.92 
50-SMA 71.35 
52-W High 99.5 
52-W Low 40.0001 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.59/-6.47
Enterprise Value
3.63B
Balance Sheet
Book Value Per Share
14.51
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.2301+0.5162+72.31%0.2PE
KPTIKaryopharm Therapeutics Inc.0.0852-0.0031-3.51%-- 
GERNGeron Corp1.035+0.105+11.29%-- 
INOInovio Pharmaceuticals1.655-0.005-0.30%-- 
NRIXNurix Therapeutics16.31-9.51-36.83%10.63PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.